{"type":"trials","record":{"id":430,"source_id":"clinicaltrials-gov","external_id":"NCT03178149","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","brief_summary":"Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult. ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD. Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. Peo…","overall_status":"Recruiting","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Astellas Institute for Regenerative Medicine","enrollment":42,"countries":["United States"],"start_date":"2018-07-13","completion_date":"2027-12-31","last_update_date":"2026-09-03","source_url":"https://clinicaltrials.gov/study/NCT03178149","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:45:04.929625+00:00","last_seen_at":"2026-09-15T00:18:36.032+00:00","metadata":{"acronym":null,"organization":"Astellas Pharma Inc","source_has_results":false},"controlled_terms":[],"relevance_confidence":68,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Published automatically with 68% topic confidence after controlled-term evaluation.","quality_checked_at":"2026-09-15T02:15:56.576005+00:00","duplicate_cluster_key":"registry:nct03178149","duplicate_of_id":null,"clinical_trial_topics":[{"topic_slug":"stem-cells","is_published":true,"match_reasons":["Legacy trial evaluated automatically against controlled title, summary, and longevity-context rules."],"matched_fields":["abstract"],"relevance_score":68,"intelligence_topics":{"name":"Stem cells","slug":"stem-cells"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/430","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}